6-Bromoindirubin-3′oxime (BIO) decreases proliferation and migration of canine melanoma cell lines. Issue 2 (August 2015)

• Record Type: Journal Article
• Authors: Chon, Esther; Flanagan, Brandi; de Sá Rodrigues, Lucas Campos; Piskun, Caroline; Stein, Timothy J.
• Is Part Of: Veterinary journal. Volume 205:Issue 2(2015)
• Page Start: 305
• Page End: 312
• Publication Date: 2015-08
• Subjects: Veterinary medicine -- Periodicals; 636
• DOI: 10.1016/j.tvjl.2014.07.012
• Languages: English
• ISSNs: 1090-0233

Abstract

<abstract abstract-type="author" id="ab0010"> <title id="st0010">Abstract</title> <sec> <p id="sp0010">Despite recent therapeutic advances, malignant melanoma is an aggressive tumor in dogs and is associated with a poor outcome. Novel, targeted agents are necessary to improve survival. In this study, 6-bromoindirubin-3′-oxime (BIO), a serine/threonine kinase inhibitor with reported specificity for glycogen synthase kinase-3 beta (GSK-3β) inhibition, was evaluated in vitro in three canine melanoma cell lines (CML-10C2, UCDK9M2, and UCDK9M3) for β-catenin-mediated transcriptional activity, Axin2 gene and protein expression levels, cell proliferation, chemotoxicity, migration and invasion assays.</p> <p id="sp0015">BIO treatment of canine malignant melanoma cell lines at 5 µM for 72 h enhanced β-catenin-mediated transcriptional activity, suggesting GSK-3β inhibition, and reduced cell proliferation and migration. There were no significant effects on invasion, chemotoxicity, or apoptosis. The results suggest that serine/threonine kinases may be viable therapeutic targets for the treatment of canine malignant melanoma.</p> </sec> </abstract>